Systemic Lupus Erythematosus - Drug Pipeline Landscape, 2022

Systemic lupus erythematosus (SLE) also referred as lupus. It is a chronic, inflammatory autoimmune disease with multiorgan involvement. In this condition, the body attacks its own immune system and causes inflammation as well as tissue damage.

The main goal of the SLE treatment is to avoid known triggering factors, preventing from tissue damage, reducing comorbidities secondary to lupus and addressing fatigue and pain. And the treatment also based on the organs and systems involved as well as the severity. Mild to moderate lupus condition can be treated with NSAIDs, anti-malarial agents and corticosteroids, in severe conditions immunosuppressive agents are included.

To know more about Systemic Lupus Erythematosus's pipeline, visit - https://www.globalinsightservices.com/reports/systemic-lupus-erythematosus-drug-pipeline-landscape-2022/

The exact cause of SLE condition is still unknown. Main factors associated with disease development and activity are environmental triggers, genetic predisposition and hormonal milieu interplay.

The common symptoms associated with SLE are inflamed joints, fatigue, fever, mouth ulcers, swollen lymph nodes, hair loss, chest pain, rashes mostly on face and anemia.

The primary diagnosis of SLE can be determined by any of the symptoms and signs. The diagnosis also involves physical examination, blood and urine tests, and skin or kidney biopsy. Other tests that are involved in confirming the severity are antinuclear antibodies (ANA) and anti-double stranded (ds) DNA (anti-dsDNA) test, CBC with differentials, urine analysis and chemistry profile including renal and liver enzymes.

To Remain 'Ahead' Of Your Competitors, Request for A Sample - https://www.globalinsightservices.com/request-sample/GIS31103

Report Segmentation
Assessment by Stage of Development
Assessment by Companies
Assessment by Target
Assessment by Mechanism of Action
Assessment by Molecule Type
Assessment by Route of Administration

Key Players
• AbbVie
• Abcentra LLC
• Accro BioScience (Suzhou) Co Ltd
• Alexion Pharmaceuticals
• Aluda Pharmaceuticals Inc
• Amgen Inc
• Ampio Pharmaceuticals Inc
• ANNEXON INC
• Apellis Pharmaceuticals, Inc
• Aria Pharmaceuticals Inc
• Asahi Kasei Pharma Corporation
• AstraZeneca
• Athos Therapeutics
• Aurinia Pharmaceuticals Inc
• Avotres Inc
• BeiGene
• Beijing Mabworks Biotech Co Ltd

Get Customized Report as Per Your Requirement - https://www.globalinsightservices.com/inquiry-before-buying/GIS31103

Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

For In-Depth Competitive Analysis, Purchase this Report - https://www.globalinsightservices.com/inquiry-before-buying/GIS31103

With Global Insight Services, you receive:
• 10-year forecast to help you make strategic decisions
• In-depth segmentation which can be customized as per your requirements
• Free consultation with lead analyst of the report
• Excel data pack included with all report purchases
• Robust and transparent research methodology

Contact Us:
Global Insight Services LLC
16192, Coastal Highway, Lewes DE 19958
E-mail: info@globalinsightservices.com
Phone: +1-833-761-1700

About Global Insight Services:
Global Insight Services (GIS) is a leading multi-industry market research firm
headquartered in Delaware, US. We are committed to providing our clients
with highest quality data, analysis, and tools to meet all their market research
needs. With GIS, you can be assured of the quality of the deliverables, robust
and transparent research methodology, and superior service.

This release was published on openPR.